Review article · 2022 · Open access
Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview
Frontiers in Pharmacology, 13, 933457 · Published 24 August 2022 · DOI 10.3389/fphar.2022.933457
In brief
“Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview” is a 2022 review article by Abdullah K. Alshememry and 4 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 22 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.
- Citations
- 22
- Most cited in
- 2026 (11)
- Field-weighted impact
- 0.17
- References
- 139
- Authors
- 5
Abstract
Pancreatic cancer (PC) remains one of the most lethal and incurable forms of cancer and has a poor prognosis. One of the significant therapeutic challenges in PC is multidrug resistance (MDR), a phenomenon in which cancer cells develop resistance toward administered therapy. Development of novel therapeutic platforms that could overcome MDR in PC is crucial for improving therapeutic outcomes. Nanotechnology is emerging as a promising tool to enhance drug efficacy and minimize off-target responses via passive and/or active targeting mechanisms. Over the past decade, tremendous efforts have been made to utilize nanocarriers capable of targeting PC cells while minimizing off-target effects. In this review article, we first give an overview of PC and the major molecular mechanisms of MDR, and then we discuss recent advancements in the development of nanocarriers used to overcome PC drug resistance. In doing so, we explore the developmental stages of this research in both pre-clinical and clinical settings. Lastly, we discuss current challenges and gaps in the literature as well as potential future directions in the field.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Alshememry, A. K., Alsaleh, N. B., Alkhudair, N. A., Alzhrani, R. M., & Alshamsan, A. (2022). Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Frontiers in Pharmacology, 13, 933457. https://doi.org/10.3389/fphar.2022.933457
MLA 9
Alshememry, Abdullah K., et al. “Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.” Frontiers in Pharmacology, vol. 13, 2022, p. 933457. https://doi.org/10.3389/fphar.2022.933457.
Chicago
Alshememry, Abdullah K., Nasser B. Alsaleh, Nora A. Alkhudair, Rami M. Alzhrani, and Aws Alshamsan. 2022. “Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.” Frontiers in Pharmacology 13: 933457. https://doi.org/10.3389/fphar.2022.933457.
Harvard
Alshememry, A. K. et al. (2022) ‘Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview’, Frontiers in Pharmacology, 13, p. 933457. doi:10.3389/fphar.2022.933457.
IEEE
A. K. Alshememry, N. B. Alsaleh, N. A. Alkhudair, R. M. Alzhrani, and A. Alshamsan, “Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview,” Frontiers in Pharmacology, vol. 13, p. 933457, 2022, doi: 10.3389/fphar.2022.933457.
BibTeX
@article{alshememry2022recent,
title = {{Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview}},
author = {Alshememry, Abdullah K. and Alsaleh, Nasser B. and Alkhudair, Nora A. and Alzhrani, Rami M. and Alshamsan, Aws},
journal = {Frontiers in Pharmacology},
year = {2022},
volume = {13},
pages = {933457},
doi = {10.3389/fphar.2022.933457},
url = {https://doi.org/10.3389/fphar.2022.933457}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 5 | |
| 2024 | 1 | |
| 2025 | 4 | |
| 2026 | 11 |
Its field-weighted citation impact is 0.17: it has been cited 0.17 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- pancreatic cancer
- multidrug resistance
- nanocarriers
- drug delivery
- active targeting
- passive targeting
- drug resistance mechanisms
- off-target effects
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Alshememry, A. K., Alsaleh, N. B., Alkhudair, N. A., Alzhrani, R. M., & Alshamsan, A. (2022). Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Frontiers in Pharmacology, 13, 933457. https://doi.org/10.3389/fphar.2022.933457
How many times has this paper been cited?
22 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Pharmacology: sign in and open the PDF from this page.
Who wrote this paper?
Abdullah K. Alshememry, Nasser B. Alsaleh, Nora A. Alkhudair, Rami M. Alzhrani, Aws Alshamsan.
What is the DOI of this paper?
10.3389/fphar.2022.933457, permanently at https://doi.org/10.3389/fphar.2022.933457. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.